REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Historical Holders from Q1 2014 to Q3 2025

Symbol: REGN on Nasdaq
Type / Class: Equity / COMMON STOCK
Shares outstanding: 104,986,330
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 86,887,634
Holdings value: $48,871,832,699
% of all portfolios: 0.032%
Number of holders: 1,223
Number of buys: 636
Number of sells: -524
Average buys %: +0.01%
Average sells %: -0.01%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
JPMORGAN CHASE & CO	4.4%	-14%	$2,729,989,170	-$462,704,633	4,742,611	-14.5%	JPMORGAN CHASE & CO.	30 May 2025
FMR LLC	3.2%	-55%	$1,880,548,739	-$2,703,197,470	3,359,562	-59%	FMR LLC	30 Jun 2025

Institutional Holders of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	86,887,634	$48,871,832,699	-$1,217,254,815	$890,604,882	$1,354,111,469	$562.27	1,223
2025 Q2	89,209,869	$46,858,212,368	-$1,426,701,600	$891,077,204	$1,031,185,485	$525	1,192
2025 Q1	92,030,457	$58,330,479,204	-$1,189,685,324	$883,151,254	$872,295,968	$634.23	1,275
2024 Q4	93,286,684	$66,492,644,189	-$479,615,848	$980,104,285	$1,080,401,248	$712.33	1,299
2024 Q3	92,775,414	$97,325,332,836	-$1,389,777,813	$1,582,219,661	$1,281,291,825	$1,051.24	1,377
2024 Q2	94,041,724	$98,807,158,234	+$1,312,660,088	$1,357,989,745	$950,660,212	$1,051.03	1,326
2024 Q1	92,759,471	$89,156,855,451	+$2,508,878,899	$1,409,151,548	$800,674,923	$962.49	1,301
2023 Q4	91,348,974	$80,250,681,450	+$167,710,733	$1,517,840,976	$1,058,609,527	$878.29	1,264
2023 Q3	91,165,414	$75,038,056,657	-$525,679,317	$1,360,513,390	$1,253,650,457	$822.96	1,169
2023 Q2	91,953,885	$66,140,528,710	-$553,052,249	$1,375,292,422	$1,191,019,132	$718.54	1,156
2023 Q1	92,595,818	$76,020,982,589	+$89,011,870	$1,711,281,088	$1,554,312,772	$821.67	1,182
2022 Q4	92,696,176	$66,864,723,638	-$266,120,511	$1,392,247,757	$1,061,813,107	$721.49	1,147
2022 Q3	92,906,259	$64,040,087,013	-$168,708,759	$1,338,955,000	$1,030,487,463	$688.87	1,066
2022 Q2	93,068,613	$55,019,554,470	+$640,020,015	$830,661,000	$572,709,000	$591.13	1,053
2022 Q1	92,282,918	$64,432,639,590	+$1,537,895,341	$1,065,718,440	$640,256,766	$698.42	1,082
2021 Q4	90,102,844	$56,873,192,901	+$52,711,404	$1,372,509,000	$868,706,000	$631.52	1,065
2021 Q3	90,013,397	$54,432,928,676	+$779,583,867	$1,363,247,000	$1,047,432,000	$605.18	1,008
2021 Q2	88,855,592	$49,577,081,270	-$361,559,165	$1,190,602,000	$940,616,000	$558.54	959
2021 Q1	89,440,318	$42,282,450,124	-$390,555,615	$1,326,386,000	$840,057,796	$473.14	906
2020 Q4	90,316,473	$43,589,271,335	-$890,178,034	$1,177,197,100	$874,735,000	$483.11	892
2020 Q3	91,983,733	$51,497,235,324	-$511,019,782	$878,973,000	$842,625,000	$559.78	899
2020 Q2	92,590,578	$57,723,182,729	+$10,927,851,201	$969,733,385	$1,003,538,000	$623.65	923
2020 Q1	75,018,948	$36,621,954,337	+$962,200,288	$863,671,000	$942,225,000	$488.29	802
2019 Q4	73,748,017	$27,687,657,792	+$214,177,689	$792,779,000	$677,817,000	$375.48	686
2019 Q3	73,531,027	$20,397,221,917	-$56,344,089	$489,029,000	$455,180,000	$277.4	615
2019 Q2	73,672,018	$23,050,091,718	-$88,569,727	$566,536,000	$456,886,000	$313	649
2019 Q1	73,893,704	$30,322,408,939	+$403,604,659	$727,325,000	$473,584,000	$410.62	703
2018 Q4	73,180,451	$27,332,195,171	-$157,698,682	$740,951,000	$654,128,000	$373.5	658
2018 Q3	73,586,468	$29,729,310,651	+$467,693,099	$885,169,000	$695,379,000	$404.04	631
2018 Q2	72,541,663	$25,025,110,595	+$77,686,718	$641,364,000	$509,412,000	$344.99	611
2018 Q1	72,288,934	$24,889,114,663	+$217,451,545	$774,566,440	$557,348,948	$344.36	610
2017 Q4	71,399,076	$26,844,190,218	-$489,810,414	$1,139,030,352	$1,199,433,708	$375.96	627
2017 Q3	72,344,472	$32,340,696,308	-$332,091,791	$1,077,471,000	$937,046,000	$447.12	598
2017 Q2	73,000,243	$35,847,977,289	+$1,272,746,514	$1,293,366,000	$1,282,240,000	$491.14	593
2017 Q1	71,894,137	$27,857,921,756	+$2,362,709,719	$719,793,000	$703,102,000	$387.51	570
2016 Q4	71,764,033	$26,345,990,159	-$641,633,351	$637,593,000	$697,546,000	$367.09	570
2016 Q3	73,533,826	$29,548,540,482	+$474,492,825	$678,610,000	$602,363,000	$402.02	546
2016 Q2	72,453,964	$25,316,735,783	-$80,452,734	$482,405,000	$527,815,000	$349.23	533
2016 Q1	72,548,546	$26,150,397,007	-$309,874,125	$384,710,000	$394,309,000	$360.44	539
2015 Q4	73,174,000	$39,723,882,129	-$79,287,903	$790,927,000	$543,272,000	$542.87	572
2015 Q3	73,229,090	$34,060,430,264	-$210,641,854	$722,807,000	$487,646,000	$465.14	553
2015 Q2	73,811,559	$37,655,809,796	+$414,401,121	$723,232,000	$520,219,000	$510.13	536
2015 Q1	72,958,000	$32,934,634,624	+$441,453,646	$620,044,000	$410,864,000	$451.48	504
2014 Q4	72,038,036	$29,554,336,522	+$161,167,975	$667,208,000	$498,333,000	$410.25	506
2014 Q3	71,645,964	$25,826,003,495	-$604,408,877	$438,718,000	$284,973,000	$360.52	471
2014 Q2	73,368,344	$20,726,843,276	-$36,098,810	$344,369,000	$196,451,000	$282.47	444
2014 Q1	73,402,366	$22,037,080,841	-$740,153,368	$381,851,000	$270,574,000	$300.28	448